Skip to content

Intelligent-Community Grid Management of Atrial Fibrillation: A Prospective, Community-based,Cluster-Randomized Controlled Trial

Intelligent-Community Grid Management of Atrial Fibrillation: A Prospective, Community-based,Cluster-Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036437
Enrollment
Unknown
Registered
2020-08-23
Start date
2021-06-01
Completion date
Unknown
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Intervention group:Intelligent-Community Grid Management of Atrial Fibrillation (ICGM-AF)
Control group:Conventional atrial fibrillation

Sponsors

Shanghai First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 60 to 80 years old; 2. Previous diagnosis of atrial fibrillation and having an electrocardiogram of atrial fibrillation; 3. CHA2DS2-VASc score >=2 for men and >=3 for women; 4. Patients are willing to sign informed consent to participate in this study; 5. Patients can complete the study according to the study protocol.

Exclusion criteria

Exclusion criteria: 1. Do not meet the inclusion criteria; 2. Congenital heart disease, mental disease, dementia or neurological disorders; 3. Severe liver and kidney dysfunction; 4. Prosthetic valve replacement, or valve diseases that require surgical treatment within the last 3 years; 5. Atrial fibrillation with reversible cause (e.g. cardiac surgery, pulmonary embolism, untreated hyperthyroidism); 6. The expected survival time was less than 2 years; 7. The patients were accompanied with other diseases that need long-term anticoagulant therapy 8. Previous invasive treatment for atrial fibrillation (surgical or catheter-interventional, including maze surgery, catheter ablation, left atrial appendage occlusion, etc.); 9. Currently participating in clinical research of any experimental drug or device.

Design outcomes

Primary

MeasureTime frame
Anticoagulant treatment rate;

Secondary

MeasureTime frame
Rate of continious anticoagulant treatment;Initiation rate of anticoagulant treatment;All-Cause Mortality;Stroke rate;Incidence rate of transient ischemic attack;Incidence rate of systemic embolism;Incidence rate of massive haemorrhage;

Countries

China

Contacts

Public ContactWei Yong

Shanghai First People's Hospital

weiyong202@qq.com+86 18918288889

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026